[Dermatofibrosarcoma protuberans]

Area of Science:

• Oncology
• Dermatology
• Genetics

Context:

• Dermatofibrosarcoma protuberans (DFSP) is the most common cutaneous sarcoma.
• DFSP exhibits slow, locally destructive growth with rare metastasis.
• Diagnosis is often delayed due to non-specific clinical presentation.

Purpose:

• To discuss the characteristics, diagnosis, and treatment of DFSP.
• To highlight the genetic underpinnings of DFSP and its therapeutic implications.
• To introduce targeted therapy for advanced or metastatic DFSP.

Summary:

• DFSP treatment typically involves wide surgical excision (2-3 cm margins) to minimize local recurrence.
• Radiation therapy is an option for surgically incurable or metastatic cases.
• A specific chromosomal translocation (17;22) in 90% of DFSP cases leads to continuous PDGFbeta pathway activation.

Impact:

• The identification of the PDGFbeta pathway activation has paved the way for molecular targeted therapies.
• Imatinib, a multikinase inhibitor, is the first registered targeted drug for advanced/metastatic DFSP.
• Imatinib demonstrated a significant response rate of approximately 70% in clinical trials for DFSP.